Yong-Yeon Cho | Biochemistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Prof. Yong-Yeon Cho | Biochemistry | Best Researcher Award

Professor at The Catholic University of Korea | South Korea

Prof.Yong-Yeon Cho is an accomplished biochemistry researcher recognized for his extensive contributions to molecular signaling, cancer biology, and drug development. His academic foundation includes rigorous training in biology, somatic cell genetics, and applied genetic engineering, forming the base for a career deeply rooted in experimental science and biochemical innovation. Over the years, he has held progressive research and academic positions, gaining broad expertise across molecular mechanisms of disease, pharmacological modulation, and therapeutic strategies. His research experience spans cellular signaling pathways, regulated cell death mechanisms, cancer chemoprevention, drug metabolism, nanoparticle-based delivery systems, immunological regulation, and translational pharmacology. He has made notable scientific contributions in areas such as ERK/RSK2 pathway targeting, UVB-induced autophagy, NLRP3 inflammasome regulation, organelle-targeted drug delivery, and the molecular foundations of metabolic and inflammatory diseases. His publication record reflects an exceptional level of productivity and global impact, with 186 peer-reviewed documents, 11,758 citations by 10,635 documents, and an impressive h-index of 49, demonstrating both the depth and influence of his work. His studies appear in leading journals across biochemistry, molecular biology, pharmacology, toxicology, and cancer research, highlighting his sustained commitment to advancing fundamental understanding while also bridging discoveries with potential clinical applications. His research interests continue to evolve across biochemical signaling networks, therapeutic biomaterials, immune regulation, toxicokinetics, and disease-associated molecular pathways, reflecting a multidisciplinary approach that integrates basic science with translational relevance. Throughout his career, he has collaborated on diverse scientific projects, contributed to international research initiatives, and helped develop emerging strategies for treating cancer, metabolic disorders, inflammatory diseases, and conditions driven by dysregulated cellular processes. Beyond producing high-impact research, he has also supported scientific progress through mentorship, scholarly leadership, and contributions to scientific discourse in multiple professional societies. His ongoing work continues to expand the boundaries of biochemistry and molecular medicine, positioning him as a leading figure whose research advances scientific knowledge while informing next-generation therapeutic innovations.

Profile: Scopus | Orcid | Google Scholar

Featured Publications:

Cho, Y.-Y.(2025). Loss of TC-PTP in keratinocytes leads to increased UVB-induced autophagy. Cell Death Discovery.

Cho, Y.-Y.(2025). Metabolite phenotyping of kobusin and identification of glutathione conjugates with kobusin catechol metabolite. Biomedicine & Pharmacotherapy.

Cho, Y.-Y.(2025). RSK2 and its binding partners: An emerging signaling node in cancers. [Journal name unavailable – Review article].

Cho, Y.-Y.(2025). Extracts from Allium pseudojaponicum Makino target STAT3 signaling pathway to overcome cisplatin resistance in lung cancer. Marine Drugs.

Cho, Y.-Y.(2024). SPOP-mediated RIPK3 destabilization desensitizes LPS/sMAC/zVAD-induced necroptotic cell death. Cellular and Molecular Life Sciences.

Cho, Y.-Y., Kim, M., Lee, S., et al. (2024). Safe and efficient treatment of drug-resistant colorectal cancer cells using kaempferol-loaded exosomes. Biotechnology and Bioprocess Engineering.

Cho, Y.-Y.(2024). RSK2-mediated cGAS phosphorylation induces cGAS chromatin-incorporation-mediated cell transformation and cancer cell colony growth. Cell Death Discovery.

Cho, Y.-Y.(2024). Ribosomal S6 kinase 2–forkhead box protein O4 signaling pathway plays an essential role in melanogenesis. Scientific Reports.

Cho, Y.-Y.(2024). Hepatocyte-specific RIG-I loss attenuates metabolic dysfunction-associated steatotic liver disease in mice via changes in mitochondrial respiration and metabolite profiles. Toxicological Research.

Cho, Y.-Y.(2024). Selective delivery of imaging probes and therapeutics to the endoplasmic reticulum or Golgi apparatus: Current strategies and beyond. Advanced Drug Delivery Reviews.

Kristian Galanti | Genetics and Molecular Biology | Best Researcher Award

Posted on by Phenomenological Research Awards

Dr. Kristian Galanti | Genetics and Molecular Biology | Best Researcher Award

Medico Specializzando at Università degli Studi G. D’Annunzio di Chieti-Pescara | Italy

Dr. Kristian Galanti is a dedicated Resident Doctor in Cardiovascular Diseases and a PhD candidate in Medical Biotechnologies at the University G. D’Annunzio of Chieti-Pescara. He currently serves as a Research Fellow at the Center for Inherited Cardiovascular Disease, WellSpan Health, USA. His clinical interests include heart failure, cardiomyopathies, and cardiovascular imaging. Dr. Galanti demonstrates exceptional commitment to evidence-based care, contributing to both patient management and research. Known for his strong collaborative ethos, he has been actively involved in multidisciplinary case presentations, cardiovascular imaging, and the development of aetiology-oriented diagnostics in cardiology.

Profile:

 Orcid

Education

Dr. Kristian Galanti’s academic journey began with a Master’s Degree in Medicine and Surgery from the Catholic University of the Sacred Heart, Rome, graduating with professional qualification. He undertook further specialization in Cardiovascular Diseases at the University G. D’Annunzio of Chieti-Pescara and is currently pursuing a PhD in Medical Biotechnologies with a focus on technological innovation in cardiovascular sciences. His education is enriched with certifications in cardiac magnetic resonance, echocardiography, and cardiogenetic imaging from leading Italian and European cardiology societies, highlighting his pursuit of continuous learning and academic excellence in clinical and translational cardiology.

Experience:

Dr. Kristian Galanti has significant clinical and research experience. As a resident physician, he managed cardiology cases, conducted ECGs, and performed advanced imaging techniques including echocardiograms and cardiac MRIs. He also participated in interventional procedures, such as angioplasties and device implantations. At WellSpan Health, he contributes to inherited cardiovascular disease research, integrating imaging and genetics to understand arrhythmogenic mitral valve prolapse. He actively engages in writing scientific articles, producing scientific illustrations, and collaborating in multinational studies, making his dual expertise in clinical and research environments a rare and impactful combination.

Research Interest:

Dr. Kristian Galanti’s research centers on cardiovascular imaging, heart failure, and genetic cardiomyopathies. He is particularly focused on multimodality cardiovascular imaging (CMR, echo) and its correlation with genetic markers in diseases like dilated cardiomyopathy and mitral valve prolapse. His current projects involve imaging-genetics integration for arrhythmic risk stratification. Dr. Galanti is also engaged in drug interaction studies related to novel heart failure therapies. Through systematic reviews and original investigations, his work aims to bridge diagnostic precision with therapeutic personalization, making significant contributions to cardiogenetics and translational cardiovascular science.

Awards and Honors:

Dr. Kristian Galanti has earned several accolades for his academic and research contributions. He received the Italian Society of Cardiology Research Grant for excellence in cardiovascular science. Additionally, he was honored with the “Aldo Prosperini” Award for his original research on ejection fraction evaluation. he won the Best Poster Award at the ANMCO MUMA Congress for his clinical case on Cori-Forbes disease. Previous honors include the Clinical Case Award and Best Abstract Award from the Italian Society of Cardiology, along with the prestigious “Iginio Betti” Foundation Scholarship.

Publications:

Title: Diagnosis and management of dilated cardiomyopathy: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

Citation: 20

year of Publications: 2024

Title: Arrhythmogenic Cardiomyopathy: Diagnosis and Management

Citation: 18

year of Publications: 2025

Title: Managing drug–drug interactions with mavacamten: a practical guide for clinicians

Citation: 15

year of Publications: 2024

Title: Arrhythmogenic mitral valve prolapse: from clinical features to imaging and genetics

Citation: 10

year of Publications: 2024

Title: Left ventricular non-compaction cardiomyopathy and related phenotypes: diagnosis, prognosis and treatment

Citation: 9

year of Publications: 2025

Title: Current antithrombotic treatments in heart failure: a review

Citation: 7

year of Publications: 2024

Title: Dilated cardiomyopathy evaluation with Imagenomics: combining multimodal cardiovascular imaging and genetics

Citation: 1

year of Publications: 2024

Conclusion:

Dr. Kristian Galanti exemplifies the ideal nominee for a Best Researcher Award. With a solid foundation in clinical cardiology and a progressive academic track in cardiovascular biotechnologies, he combines precision medicine, imaging innovation, and genetic insights in his work. His publication record, international research fellowships, and prestigious recognitions reflect his role as a rising leader in cardiovascular research. Dr. Galanti’s commitment to collaborative science, continual learning, and impactful patient care affirms his readiness to shape the future of cardiovascular medicine with compassion, innovation, and academic rigor.